By Research Area
Hot products 
-
Mouse Anti-ALOX5 Recombinant Antibody (33) (CBMAB-1890CQ)
-
Mouse Anti-CA9 Recombinant Antibody (CBXC-2079) (CBMAB-C0131-CQ)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CR3022) (CBMAB-CR014LY)
-
Rat Anti-C5AR1 Recombinant Antibody (8D6) (CBMAB-C9139-LY)
-
Mouse Anti-CCL18 Recombinant Antibody (64507) (CBMAB-C7910-LY)
-
Mouse Anti-CD164 Recombinant Antibody (CBFYC-0077) (CBMAB-C0086-FY)
-
Mouse Anti-ARID1B Recombinant Antibody (KMN1) (CBMAB-A3546-YC)
-
Rabbit Anti-ALK (Phosphorylated Y1278) Recombinant Antibody (D59G10) (PTM-CBMAB-0035YC)
-
Mouse Anti-BrdU Recombinant Antibody (IIB5) (CBMAB-1038CQ)
-
Mouse Anti-APCS Recombinant Antibody (CBYC-A663) (CBMAB-A3054-YC)
-
Mouse Anti-4-Hydroxynonenal Recombinant Antibody (V2-502280) (CBMAB-C1055-CN)
-
Mouse Anti-BSN Recombinant Antibody (219E1) (CBMAB-1228-CN)
-
Mouse Anti-Acetyl SMC3 (K105/K106) Recombinant Antibody (V2-634053) (CBMAB-AP052LY)
-
Mouse Anti-CAPZB Recombinant Antibody (CBYY-C0944) (CBMAB-C2381-YY)
-
Rat Anti-FABP3 Recombinant Antibody (CBXF-2299) (CBMAB-F1612-CQ)
-
Rat Anti-ABCC11 Recombinant Antibody (V2-179001) (CBMAB-A0236-YC)
-
Mouse Anti-ADGRE5 Recombinant Antibody (V2-360335) (CBMAB-C2088-CQ)
-
Mouse Anti-ADAM12 Recombinant Antibody (V2-179752) (CBMAB-A1114-YC)
-
Mouse Anti-ATM Recombinant Antibody (2C1) (CBMAB-A3970-YC)
-
Mouse Anti-ALB Recombinant Antibody (V2-55272) (CBMAB-H0819-FY)
Lung Cancer Research
Lung cancer, formally known as primary bronchogenic carcinoma, originates from the epithelial cells of the bronchial mucosa or glands, which is one of the most prevalent malignancies worldwide. It is primarily classified into non-small cell lung cancer (NSCLC) and SCLC based on histopathological characteristics. While lung cancer is non-contagious, it exhibits significant familial clustering and genetic susceptibility. Common causes of lung cancer involve smoking, occupational exposure, and air pollution. According to the latest global cancer report released by the International Agency for Research on Cancer (IACR) in 2024, lung cancer ranks first in both new cases (12.4%) and deaths (18.7%), making it the leading cancer worldwide, particularly among men.
Discover our advanced antibody products, which will significantly enhance your work in lung cancer diagnosis and treatment research. These antibodies are carefully designed to possess high specificity and sensitivity, enabling accurate biomarker identification and assessment.
Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols
Reference
- Lahiri, Aritraa, et al. "Lung cancer immunotherapy: progress, pitfalls, and promises." Molecular cancer 22.1 (2023): 40. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only Part B of the original image.
Loading...
Compare
